Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 2/20 | 0.37 |
| ▸ | TRPA1 | O75762 | 4/20 | 0.36 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19795386 | 0.82 | TRPA1 (0.42) | PTGS2TRPA1POLB | |
| SCHEMBL19795013 | 0.80 | TRPA1 (0.40) | PTGS2TRPA1POLBKMT2AALDH1A1 | |
| SCHEMBL14304515 | 0.79 | PTGS2 (0.58) | PTGS2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL12424374 | 0.78 | POLB (0.54) | PTGS2TRPA1POLBKMT2AALDH1A1 | |
| SCHEMBL26136150 | 0.77 | PTGS2 (0.42) | PTGS2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL1002604 | 0.77 | PTGS2 (0.42) | PTGS2POLBKMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL19807684 | 0.75 | TRPA1 (0.45) | TRPA1FGFR1DGAT1 | |
| SCHEMBL18017677 | 0.75 | TRPA1 (0.46) | TRPA1FGFR1DGAT1 | |
| SCHEMBL21010418 | 0.72 | TRPA1 (0.43) | TRPA1FGFR1DGAT1 | |
| SCHEMBL20997476 | 0.72 | TRPA1 (0.45) | TRPA1FGFR1KMT2AALDH1A1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3487853-B1 | BICYCLIC PROLINE COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2022-06-08 | — | — | EP | disclosed |
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | GENENTECH, INC. (US) | 2019-05-16 | — | — | US | disclosed |
| WO-2018015410-A1 | BICYCLIC PROLINE COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2018-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144428-A1 | BICYCLIC PROLINE COMPOUNDS | TRPA1, TRPV1, TRPV5 | PTGS2 132/4885TRPA1 1/4885FGFR1 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.